A multi-centre study to investigate the natural history of taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast or prostate cancer.

e21594Background: Taxane acute pain syndrome (TAPS) is characterized by myalgia and arthralgia starting 24-48 hours after receiving taxane-based chemotherapy and lasting up to 7 days. Despite its negative impact on patient quality of life (QoL), its characteristics and natural history remain poorly defined. The present study evaluates persistence, severity and the impact of TAPS on QoL. Methods: Breast or prostate cancers patients commencing taxane-based chemotherapy completed the Functional Assessment of Cancer Therapy-Taxane (FACT-T), Brief Pain Inventory (BPI) questionnaires and a pain medication diary every day for 1 week after each chemotherapy infusion. Results: From March to December 2015, of 52 patients enrolled, 25 (breast n=21, prostate n=4) completed the study. TAPS started 24-72 hours (range 24-96) after infusion reaching a peak by day 3 (range 1-5), and was more often reported in the legs and back. Table 1 shows the TAPS characteristics. There were no dose reductions, delays or treatment disc...